TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy
Chenxi Cheng, Ting Liang, Pengju Yao, Wenling Wang et autres
0 citationsScience Advances
Fuming Qiu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
76Publications signalées
3518Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
HER2/EGFR in Cancer ResearchImmune cells in cancerImmune Cell Function and InteractionCancer Treatment and PharmacologyCancer Immunotherapy and Biomarkers
Publications récentes
Benmelstobart plus antiangiogenic therapy vs chemotherapy for metastatic triple-negative breast cancer: phase III trial
Jiayu Wang, Quchang Ouyang, Zhihong Wang, Qingyuan Zhang et autres
0 citationsnpj Breast Cancer
Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer
Bo Lan, Faliang Xu, Tao Sun, Fuming Qiu et autres
0 citationsSignal Transduction and Targeted Therapy
Adipocyte-derived LTB4 programs human NKG2A + γδ T cells as cytotoxic sentinels at the adipose-tumor interface in breast cancer
Xiaoxiao Hu, Dang Wu, Fang Jia, Sangsang Zhu et autres
0 citationsJournal for ImmunoTherapy of Cancer
Gut microbiota-derived deoxycholic acid shapes an immunosuppressive tumor microenvironment and promotes breast cancer progression
Li Li, Chenghui Yang, Zi Wang, Bangyi Zhou et autres
2 citationsCell Metabolism
Case Report: Metastasis to pleura and mediastinal lymph nodes from breast secretory carcinoma: 10 years follow-up
Fengbo Huang, Jing Zhao, Bo Hong, Xiaoyan Yu et autres
1 citationFrontiers in Oncology
Abstract P4-12-21: Efficacy and Safety of MRG002 in Prior TKI-Treated HER2 Positive Breast Cancer Patients: A Single Arm, Open Label, Multicenter, Phase II Study
Qiang Liu, Shaohua Zhang, Yaping Yang, Quchang Ouyang et autres
1 citationClinical Cancer Research
Comprehensive results of ESG401, a TROP2-targeting ADC: Updated phase 1 analysis in advanced solid tumors.
Fei Ma, Fuming Qiu, Zhongsheng Tong, Jiani Wang et autres
1 citationJournal of Clinical Oncology
IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.
Charlotte Lemech, Yuping Sun, Adnan Nagrial, Xinhong Wu et autres
1 citationJournal of Clinical Oncology
ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.
Jiayu Wang, Binghe Xu, Quchang Ouyang, Zhihong Wang et autres
2 citationsJournal of Clinical Oncology
Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study.
Fan Wu, Qian Chu, Qin Xu, Fuming Qiu et autres
2 citationsJournal of Clinical Oncology
Zinc-copper bimetallic nanoplatforms trigger photothermal-amplified cuproptosis and cGAS-STING activation for enhancing triple-negative breast cancer immunotherapy
Bangyi Zhou, Mengyao Chen, Zhixing Hao, Lili Li et autres
39 citationsJournal of Nanobiotechnology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.